Latest Conference Articles

Early allergen sensitization is associated with an increased risk of viral infections and the development of childhood asthma.

Alexia Beauregard, MS, RD, CSP, LD, explains how a food allergy specialist dietitian could make a life-saving difference in helping families understand food allergy.

As telehealth becomes more widely used, the role dietitians play in multidisciplinary teams for the treatment of allergy has increased.

The FDA previously approved DUPIXENT in the US for the treatment of adults with moderate-to-severe atopic dermatitis.

Patricia Dickson, M.D., discusses similarities between variations of MPS and the both the benefits and challenges of being a researcher in the rare disease community.

Alexy V. Pshezhetsky, Ph.D., professor at the University of Montreal. sits down at WORLDSymposium to stress the importance of researcher involvement throughout the rare disease community.

Hartmann Wellhoefer, M.D., head of medical affairs at Shire, sits down with RDR at the 14th Annual WORLDSymposium to discuss the company's recent data for lysosomal storage diseases.

With no real standard-of-care for Sanfilippo syndrome patients, Brian Bigger, Ph.D., discusses the sense of urgency he and his colleagues feel while researching.

BioMarin presented interim data at the 14th Annual WORLDSymposium in San Diego from a Phase 1/2 trial for BMN 250 in MPS IIIB.

ArmaGen reported full 52-week results from a Phase 2 proof-of-concept study with AGT-181 in MPS I.

Rare Disease Report sits down with Simon Heales, Ph.D., Professor of Clinical Chemistry at Great Ormond Street Children’s Hospital in London who discusses a potential link between Gaucher disease and Parkinson’s disease.

Sanofi Genzyme presented results from the Phase 1/2 trial, showing consistent safety data for the investigational avalglucosidase alfa in late-onset Pompe disease.

Amicus presented additional positive results from the company’s Phase 1/2 clinical study of ATB200/AT2221 in patients with Pompe disease in a late-breaker poster and a corresponding oral presentation.

Today at the WORLDSymposium in San Diego, Valerion Therapeutics presented initial results from the first cohort of its ongoing Phase 1/2 clinical study of VAL-1221 in patients with late-onset Pompe disease.

At the 14th Annual WORLDSymposium, interim data from two open-label studies were presented, exhibiting a 3-year survival estimate of 68% in infants with rapidly progressing LAL-D treated with sebelipase alfa.

Kahook Dual Blade intends to reduce intraocular pressure and the number of patient medications.

The retinal injection therapy could be capable of replacing damaged cells integral to eye vision.

Depression has been shown in research studies to correlate with the level of disability.

This new technology allows for smaller gauge with flow rate similar to that of the guillotine-based one.

The potential glaucoma and dry eye device administers 80% less topical treatment per dose.

Squalamine lactate, a topical eye drop, is studied as an add-on to anti-VEGF therapy to improve visual function.

An average 7,000 steps per day can cut glaucoma risk by up to 73%, researchers found.

The distractive spots floating through fields of vision may have finally met their match.

Researchers found racial and ethnic disparities in sites and types of injuries sustained in gunfire injuries to patients' eyes.

The multi-targeted inhibitor, a non-invasive eye drop, acts in a different way of treating the chronic disease.

The diagnostics of the disease is not only important for the initial evaluation, but also etiology and long-term management.

A study of Florida-based Veterans Affairs hospitals found trends among ocular conditions and chronic pain conditions.

As new diagnoses appear, etiology is understood better and treated better, resulting in a decrease of prevalence rates.

The smarthpone app Checkup is a preferred visual acuity test to the Amsler grid, according to study.

A study sub-analysis showed the anti-VEGF treatment maintained efficacy over longer intervals in a majority of patients.